Statistical considerations for calculation of immunogenicity screening assay cut points.

Area of Science:

• Biopharmaceutical development
• Immunology
• Statistical analysis

Background:

• Therapeutic proteins often trigger immune responses, leading to anti-drug antibodies.
• These antibodies can impact drug safety and efficacy, necessitating immunogenicity assessment during clinical development.

Purpose of the Study:

• To review and evaluate statistical approaches for determining immunogenicity screening assay cut points.
• To assess the influence of sampling design and variability on these statistical methods.
• To provide recommendations for calculating immunogenicity screening cut points.

Main Methods:

• Review of existing statistical approaches for cut point calculation.
• Evaluation of the performance of different statistical methods based on sampling design and variability.
• Comparison of 'average' versus 'confidence-level' cut points.

Main Results:

• The performance of various statistical approaches for cut point determination has not been fully evaluated.
• Sampling design and variability significantly impact the performance of statistical methods for cut point calculation.
• Differences between 'average' and 'confidence-level' cut points require further clarification.

Conclusions:

• Standardized and robust statistical methods are needed for calculating immunogenicity screening cut points.
• A thorough evaluation of statistical approaches is essential for accurate immunogenicity testing.
• Recommendations for cut point calculation will improve the strategic assessment of therapeutic protein immunogenicity.